Generic Name and Formulations:
Lincomycin 300mg/mL; soln for IV, IM, subconjunctival inj after dilution; contains benzyl alcohol 9.45mg.
Indications for LINCOCIN:
Serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Reserved for penicillin-allergic patients or for whom penicillin is inappropriate.
IV doses: infuse over ≥60mins. Serious infections: 600mg IM every 24hrs or 600mg–1g IV every 8–12hrs. More severe infections: 600mg IM every 12hrs (or more often), or doses up to max 8g/day IV have been used for life-threatening infections. Subconjunctival inj: 75mg subconjunctivally will result in ocular fluid levels of antibiotic with MICs sufficient for most susceptible pathogens. Severe renal impairment: give 25–30% of recommended dose.
<1month: not established. IV doses: infuse over ≥60mins. ≥1month: Serious infections: 10mg/kg IM every 24hrs. More severe infections: 10mg/kg IM every 12hrs or more often. Depending on severity of infection, may also give 10–20mg/kg/day IV in divided doses.
Clostridium difficile associated diarrhea.
Risk of severe colitis (may be fatal); consider C. difficile-associated diarrhea (CDAD) in all patients presenting with diarrhea after use; discontinue if CDAD suspected/confirmed or if significant diarrhea occurs. Not for treating minor bacterial or viral infections, or meningitis. History of GI disease (esp. colitis). History of asthma or significant allergies. Severe renal impairment. Hepatic dysfunction. Monitor liver, kidney, and blood counts with prolonged and high-dose therapy. Premature infants (Gasping Syndrome from benzyl alcohol). Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant erythromycin: not recommended. May potentiate neuromuscular blocking agents.
Nausea, vomiting, diarrhea, colitis, hematologic effects (eg, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura), rash, urticaria, vaginitis, jaundice, abnormal LFTs, azotemia, oliguria, proteinuria, cardiopulmonary arrest and hypotension with rapid IV administration, superinfection; CDAD, hypersensitivity or severe skin reactions (discontinue if occur).
Vials (2mL, 10mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline